Abion announced on the 27th that it will present a total of four research results in poster sessions at the American Association for Cancer Research Annual Meeting (AACR 2024). AACR will be held from April 5 to 10 (local time) in San Diego, California, USA.
The research results to be presented include ▲preclinical results of ABN501 in small cell lung cancer (SCLC) ▲preclinical results of ABN202-VISTAxMSLN (Vista? Mesothelin-targeted anticancer agent) multi-antibody ▲preclinical results of ABN202-EGFR in non-small cell lung cancer ▲preclinical results of ABN202-Trop2 targeted anticancer agent in Trop2-positive solid tumors.
The company will reveal for the first time the anticancer effects of the claudin 3 (CLDN3) targeted anticancer agent ABN501 in small cell lung cancer at this conference. Claudin 3 is a solid tumor marker that is overexpressed in various solid tumors or associated with poor prognosis. Recently, various claudin-targeted anticancer agents have been developed, and global licensing-out (LO) agreements have been signed, increasing market interest.
Abion stated, “We confirmed high claudin 3 expression in small cell lung cancer, a disease with high unmet medical needs due to the absence of approved effective targeted anticancer agents,” and added, “We are promoting the licensing-out of ABN501, which has high value as a treatment for small cell lung cancer.”
In addition, the company is preparing poster presentations for three ABN202 development pipelines. ABN202 is a targeted anticancer agent applying antibody-cytokine fusion platform technology.
A company representative emphasized, “We plan to showcase the competitiveness of our pipeline through various global conferences scheduled this year,” and added, “We will focus on research and development to enhance corporate value through active technology licensing.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
